Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now

Company Announcements

Latest announcements

Date and timeCompanyHeadlineSource
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSISPR Newswire
INVESTOR ALERT: Trip.com Group Limited (TCOM) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitPR Newswire
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesityPR Newswire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis CareBusiness Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual MeetingBusiness Wire
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific SessionBusiness Wire
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in DermatomyositisGlobeNewswire
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual MeetingGlobeNewswire
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease ActivityGlobeNewswire
CANADABIS ANNOUNCES DELAY IN FILING OF SECOND QUARTER FINANCIAL STATEMENTSCanada Newswire
Décision du tribunal américain du district Sud de New York dans le cadre du nouveau procès TriZettoGlobeNewswire
Decision of the US District Court for the Southern District of New York in the TriZetto re-trialGlobeNewswire
CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpointsPR Newswire
TCL Electronics (01070.HK) Achieving High-Quality Global Growth in 2025, with Adjusted Profit Attributable to Owners of the Parent and Dividends Surging by over 56%PR Newswire
HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolismPR Newswire
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and ExpoBusiness Wire
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasisPR Newswire
RNS announcements are delayed by up to an hour.
...